350 related articles for article (PubMed ID: 19925877)
1. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.
Kasamon YL; Luznik L; Leffell MS; Kowalski J; Tsai HL; Bolaños-Meade J; Morris LE; Crilley PA; O'Donnell PV; Rossiter N; Huff CA; Brodsky RA; Matsui WH; Swinnen LJ; Borrello I; Powell JD; Ambinder RF; Jones RJ; Fuchs EJ
Biol Blood Marrow Transplant; 2010 Apr; 16(4):482-9. PubMed ID: 19925877
[TBL] [Abstract][Full Text] [Related]
2. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
Luznik L; O'Donnell PV; Symons HJ; Chen AR; Leffell MS; Zahurak M; Gooley TA; Piantadosi S; Kaup M; Ambinder RF; Huff CA; Matsui W; Bolaños-Meade J; Borrello I; Powell JD; Harrington E; Warnock S; Flowers M; Brodsky RA; Sandmaier BM; Storb RF; Jones RJ; Fuchs EJ
Biol Blood Marrow Transplant; 2008 Jun; 14(6):641-50. PubMed ID: 18489989
[TBL] [Abstract][Full Text] [Related]
3. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.
Symons HJ; Leffell MS; Rossiter ND; Zahurak M; Jones RJ; Fuchs EJ
Biol Blood Marrow Transplant; 2010 Apr; 16(4):533-42. PubMed ID: 19961944
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.
Kasamon YL; Bolaños-Meade J; Prince GT; Tsai HL; McCurdy SR; Kanakry JA; Rosner GL; Brodsky RA; Perica K; Smith BD; Gladstone DE; Swinnen LJ; Showel MM; Matsui WH; Huff CA; Borrello I; Pratz KW; McDevitt MA; Gojo I; Dezern AE; Shanbhag S; Levis MJ; Luznik L; Ambinder RF; Fuchs EJ; Jones RJ
J Clin Oncol; 2015 Oct; 33(28):3152-61. PubMed ID: 26261255
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.
Munchel AT; Kasamon YL; Fuchs EJ
Best Pract Res Clin Haematol; 2011 Sep; 24(3):359-68. PubMed ID: 21925089
[TBL] [Abstract][Full Text] [Related]
6. Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide.
Raiola AM; Risitano A; Sacchi N; Giannoni L; Signori A; Aquino S; Bregante S; Di Grazia C; Dominietto A; Geroldi S; Ghiso A; Gualandi F; Lamparelli T; Tedone E; Van Lint MT; Varaldo R; Ibatici A; Marani C; Marotta S; Guolo F; Avenoso D; Garbarino L; Pane F; Bacigalupo A; Angelucci E
Biol Blood Marrow Transplant; 2018 Jan; 24(1):119-126. PubMed ID: 29024804
[TBL] [Abstract][Full Text] [Related]
7. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.
Ghosh N; Karmali R; Rocha V; Ahn KW; DiGilio A; Hari PN; Bachanova V; Bacher U; Dahi P; de Lima M; D'Souza A; Fenske TS; Ganguly S; Kharfan-Dabaja MA; Prestidge TD; Savani BN; Smith SM; Sureda AM; Waller EK; Jaglowski S; Herrera AF; Armand P; Salit RB; Wagner-Johnston ND; Fuchs E; Bolaños-Meade J; Hamadani M
J Clin Oncol; 2016 Sep; 34(26):3141-9. PubMed ID: 27269951
[TBL] [Abstract][Full Text] [Related]
8. Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies.
Klein OR; Buddenbaum J; Tucker N; Chen AR; Gamper CJ; Loeb D; Zambidis E; Llosa NJ; Huo JS; Robey N; Holuba MJ; Kasamon YL; McCurdy SR; Ambinder R; Bolaños-Meade J; Luznik L; Fuchs EJ; Jones RJ; Cooke KR; Symons HJ
Biol Blood Marrow Transplant; 2017 Feb; 23(2):325-332. PubMed ID: 27888014
[TBL] [Abstract][Full Text] [Related]
9. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
10. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
Ogawa H; Ikegame K; Kaida K; Yoshihara S; Fujioka T; Taniguchi Y; Tamaki H; Inoue T; Hasei H; Iiboshi Y; Tazuke Y; Kawakami M; Kim EH; Soma T; Inoue T; Kawase I
Exp Hematol; 2008 Jan; 36(1):1-8. PubMed ID: 17920757
[TBL] [Abstract][Full Text] [Related]
11. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide.
O'Donnell PV; Luznik L; Jones RJ; Vogelsang GB; Leffell MS; Phelps M; Rhubart P; Cowan K; Piantados S; Fuchs EJ
Biol Blood Marrow Transplant; 2002; 8(7):377-86. PubMed ID: 12171484
[TBL] [Abstract][Full Text] [Related]
12. Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide.
Mariotti J; Taurino D; Marino F; Bramanti S; Sarina B; Morabito L; De Philippis C; Di Vito C; Mavilio D; Carlo-Stella C; Della Porta M; Santoro A; Castagna L
Cancer Med; 2020 Jan; 9(1):52-61. PubMed ID: 31702882
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.
Kanakry JA; Gocke CD; Bolaños-Meade J; Gladstone DE; Swinnen LJ; Blackford AL; Fuchs EJ; Huff CA; Borrello I; Matsui WH; Brodsky RA; Rosner GL; Shanbhag S; Luznik L; Jones RJ; Ambinder RF; Kasamon YL
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2115-2122. PubMed ID: 26183076
[TBL] [Abstract][Full Text] [Related]
14. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
15. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.
McCurdy SR; Kanakry JA; Showel MM; Tsai HL; Bolaños-Meade J; Rosner GL; Kanakry CG; Perica K; Symons HJ; Brodsky RA; Gladstone DE; Huff CA; Pratz KW; Prince GT; Dezern AE; Gojo I; Matsui WH; Borrello I; McDevitt MA; Swinnen LJ; Smith BD; Levis MJ; Ambinder RF; Luznik L; Jones RJ; Fuchs EJ; Kasamon YL
Blood; 2015 May; 125(19):3024-31. PubMed ID: 25814532
[TBL] [Abstract][Full Text] [Related]
16. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
17. CD31 mismatching affects marrow transplantation outcome.
Grumet FC; Hiraki DD; Brown BWM ; Zehnder JL; Zacks ES; Draksharapu A; Parnes J; Negrin RS
Biol Blood Marrow Transplant; 2001; 7(9):503-12. PubMed ID: 11669217
[TBL] [Abstract][Full Text] [Related]
18. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
[TBL] [Abstract][Full Text] [Related]
19. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
[TBL] [Abstract][Full Text] [Related]
20. Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.
Kasamon YL; Fuchs EJ; Zahurak M; Rosner GL; Symons HJ; Gladstone DE; Huff CA; Swinnen LJ; Brodsky RA; Matsui WH; Borrello I; Shanbhag S; Cooke KR; Ambinder RF; Luznik L; Bolaños-Meade J; Jones RJ
Biol Blood Marrow Transplant; 2018 May; 24(5):1022-1028. PubMed ID: 29353109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
